

CASE STUDY

Randomizing >2,750 Participants in the U.S. and U.K. for a Global Phase 3 Trial

The Objective

A total of 29 Velocity sites across the U.S. and U.K. were selected to support a global Phase 3 vaccine trial. The trial required enrollment of generally healthy adults.

- **Global enrollment goal:** >23,500 participants across >250 sites
- **Velocity enrollment goal:** 2,200 participants across 29 sites
- **Target population:** Generally healthy adults

The Result

Velocity exceeded expectations, delivering >2,750 trial participants — 125% of the contracted goal.

- Velocity's High Wycombe, UK site enrolled >200 participants.
- Velocity sites outpaced average site enrollment throughout the entire trial.

The Trial

Client: Large pharma Sponsor

Trial: Multinational Phase 3 vaccine trial

Target population: Generally healthy adults

Velocity Sites

United States

- Albuquerque, NM
- Anderson, SC
- Baton Rouge, LA
- Binghamton, NY
- Boise, ID
- Cincinnati, OH (Blue Ash)
- Cincinnati, OH (Mt. Auburn)
- Cincinnati, OH (Springdale)
- Cleveland, OH
- Covington, LA
- Durham, NC
- Gulfport, MS
- Hampton, VA
- Kansas City, MO
- Lincoln, NE
- Los Angeles, CA
- Norfolk, VA
- Omaha, NE
- Portsmouth, VA
- Providence, RI
- Rockville, MD
- San Diego, CA
- Savannah, GA
- Sioux City, IA
- Spartanburg, SC
- Syracuse, NY
- Valparaiso, IN
- Vestal, NY

United Kingdom

- High Wycombe, UK